Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenneth G Saag

Showing results (311-320 of 374) with videos related to

Pageof 38
Sort By:
The Journal of Clinical Endocrinology and Metabolism|May 26, 2018
ACTIVExtend: 24 Months of Alendronate After 18 Months of Abaloparatide or Placebo for Postmenopausal OsteoporosisHenry G Bone, Felicia Cosman, Paul D Miller, et al.
Contemporary Clinical Trials|July 25, 2016
Rationale and design of the randomized evaluation of an Ambulatory Care Pharmacist-Led Intervention to Optimize Urate Lowering Pathways (RAmP-UP) StudyBrian W Coburn, T Craig Cheetham, Nazia Rashid, et al.
Clinical and Experimental Rheumatology|July 29, 2014
Fractures and mortality in relation to different osteoporosis treatmentsHuifeng Yun, Elizabeth Delzell, Kenneth G Saag, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|October 3, 2022
The Efficacy and Safety of Abaloparatide-SC in Men With Osteoporosis: A Randomized Clinical TrialEdward Czerwinski, Jose Cardona, Rafal Plebanski, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|December 13, 2022
Interactions Between Genetic Risk and Diet Influencing Risk of Incident Female Gout: Discovery and Replication Analysis of Four Prospective CohortsKehuan Lin, Natalie McCormick, Chio Yokose, et al.
Arthritis Care & Research|April 1, 2011
2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic featuresTimothy Beukelman, Nivedita M Patkar, Kenneth G Saag, et al.
Arthritis Care & Research|November 21, 2022
Development and Validation of an Emergency Department Electronic Medical Record Gout Flare AlertLesley E Jackson, Narender Annapureddy, Megan E Hansen, et al.
Medical Care|July 2, 2014
Effect of self-referral on bone mineral density testing and osteoporosis treatmentAmy H Warriner, Ryan C Outman, Adrianne C Feldstein, et al.
Annals of the Rheumatic Diseases|July 16, 2013
Non-viral opportunistic infections in new users of tumour necrosis factor inhibitor therapy: results of the SAfety Assessment of Biologic ThERapy (SABER) studyJohn W Baddley, Kevin L Winthrop, Lang Chen, et al.
JAMA|March 7, 2013
Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zosterKevin L Winthrop, John W Baddley, Lang Chen, et al.
Pageof 38

Showing results (311-320 of 374) with videos related to

Sort By:
Pageof 38
The Journal of Clinical Endocrinology and Metabolism|May 26, 2018
ACTIVExtend: 24 Months of Alendronate After 18 Months of Abaloparatide or Placebo for Postmenopausal OsteoporosisHenry G Bone, Felicia Cosman, Paul D Miller, et al.
Contemporary Clinical Trials|July 25, 2016
Rationale and design of the randomized evaluation of an Ambulatory Care Pharmacist-Led Intervention to Optimize Urate Lowering Pathways (RAmP-UP) StudyBrian W Coburn, T Craig Cheetham, Nazia Rashid, et al.
Clinical and Experimental Rheumatology|July 29, 2014
Fractures and mortality in relation to different osteoporosis treatmentsHuifeng Yun, Elizabeth Delzell, Kenneth G Saag, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|October 3, 2022
The Efficacy and Safety of Abaloparatide-SC in Men With Osteoporosis: A Randomized Clinical TrialEdward Czerwinski, Jose Cardona, Rafal Plebanski, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|December 13, 2022
Interactions Between Genetic Risk and Diet Influencing Risk of Incident Female Gout: Discovery and Replication Analysis of Four Prospective CohortsKehuan Lin, Natalie McCormick, Chio Yokose, et al.
Arthritis Care & Research|April 1, 2011
2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic featuresTimothy Beukelman, Nivedita M Patkar, Kenneth G Saag, et al.
Arthritis Care & Research|November 21, 2022
Development and Validation of an Emergency Department Electronic Medical Record Gout Flare AlertLesley E Jackson, Narender Annapureddy, Megan E Hansen, et al.
Medical Care|July 2, 2014
Effect of self-referral on bone mineral density testing and osteoporosis treatmentAmy H Warriner, Ryan C Outman, Adrianne C Feldstein, et al.
Annals of the Rheumatic Diseases|July 16, 2013
Non-viral opportunistic infections in new users of tumour necrosis factor inhibitor therapy: results of the SAfety Assessment of Biologic ThERapy (SABER) studyJohn W Baddley, Kevin L Winthrop, Lang Chen, et al.
JAMA|March 7, 2013
Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zosterKevin L Winthrop, John W Baddley, Lang Chen, et al.
Pageof 38